168 related articles for article (PubMed ID: 37492625)
21. Does red blood cell distribution width predict prognosis in metastatic renal cell carcinoma patients using first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy?
Korkmaz M; Eryılmaz MK; Koçak MZ; Er MM; Hendem E; Demirkıran A; Araz M; Karaağaç M; Artaç M
J Cancer Res Ther; 2023 Apr; 19(Supplement):S0. PubMed ID: 37147975
[TBL] [Abstract][Full Text] [Related]
22. Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison.
Santoni M; Aurilio G; Massari F; Grande E; Matrana MR; Rizzo M; De Giorgi U; Incorvaia L; Martignetti A; Molina-Cerrillo J; Zabalza IO; Mollica V; Rizzo A; Battelli N; Porta C
Clin Genitourin Cancer; 2022 Jun; 20(3):285-295. PubMed ID: 35305916
[TBL] [Abstract][Full Text] [Related]
23. First-line pazopanib in intermediate- and poor-risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial.
Staehler M; Panic A; Goebell PJ; Merling M; Potthoff K; Herrmann E; de Geeter P; Vannier C; Hogrefe C; Marschner N; Grünwald V
Int J Cancer; 2021 Feb; 148(4):950-960. PubMed ID: 32738823
[TBL] [Abstract][Full Text] [Related]
24. Cabozantinib in the treatment of metastatic renal cell carcinoma - final data analysis from four oncology centers in the Czech Republic.
Richter I; Poprach A; Zemánková A; Büchler T; Bartoš J; Šámal V; Študentová H; Rozsypalová A; Dvořák J; Brom O; Melichar B
Klin Onkol; 2021; 34(5):392-400. PubMed ID: 34915708
[TBL] [Abstract][Full Text] [Related]
25. Prognostic Value of Preoperative Red Cell Distribution Width: Fine-Tuning by Mean Corpuscular Volume.
Dai L; Mick SL; McCrae KR; Houghtaling PL; Blackstone EH; Koch CG
Ann Thorac Surg; 2019 Dec; 108(6):1830-1838. PubMed ID: 31199898
[TBL] [Abstract][Full Text] [Related]
26. Dynamic Contrast-Enhanced Computed Tomography-Derived Blood Volume and Blood Flow Correlate With Patient Outcome in Metastatic Renal Cell Carcinoma.
Mains JR; Donskov F; Pedersen EM; Madsen HH; Rasmussen F
Invest Radiol; 2017 Feb; 52(2):103-110. PubMed ID: 27513367
[TBL] [Abstract][Full Text] [Related]
27. Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.
Xie M; He CS; Huang JK; Lin QZ
Eur J Cancer; 2015 Mar; 51(5):595-603. PubMed ID: 25618828
[TBL] [Abstract][Full Text] [Related]
28. Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced non-small cell lung cancer patients.
Buti S; Bordi P; Tiseo M; Bria E; Sperduti I; Di Maio M; Panni S; Novello S; Rapetti SG; Pilotto S; Genestreti G; Rossi A; Pezzuolo D; Camisa R; Tortora G; Ardizzoni A
Lung Cancer; 2015 Jun; 88(3):319-24. PubMed ID: 25870156
[TBL] [Abstract][Full Text] [Related]
29. Pazopanib in Metastatic Renal Cancer: A "Real-World" Experience at National Cancer Institute "Fondazione G. Pascale".
Cecere SC; Rossetti S; Cavaliere C; Della Pepa C; Di Napoli M; Crispo A; Iovane G; Piscitelli R; Sorrentino D; Ciliberto G; Maiolino P; Muto P; Perdonà S; Berretta M; Pignata S; Facchini G; D'Aniello C
Front Pharmacol; 2016; 7():287. PubMed ID: 27630568
[TBL] [Abstract][Full Text] [Related]
30. Hypertension as a prognostic factor in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: a systematic review and meta-analysis.
Liu Y; Zhou L; Chen Y; Liao B; Ye D; Wang K; Li H
BMC Urol; 2019 Jun; 19(1):49. PubMed ID: 31174518
[TBL] [Abstract][Full Text] [Related]
31. The application value of mean red blood cell volume and red blood cell volume distribution width combined with total serum bilirubin in the early screening of neonatal hemolytic disease.
Lin H; Luo P; Liu C; Lin X; Que C; Zhong W
BMC Pediatr; 2023 Jan; 23(1):19. PubMed ID: 36639749
[TBL] [Abstract][Full Text] [Related]
32. Changes in the mean corpuscular volume after capecitabine treatment are associated with clinical response and survival in patients with advanced gastric cancer.
Jung HA; Kim HJ; Maeng CH; Park SH; Lee J; Park JO; Park YS; Lim HY; Kang WK
Cancer Res Treat; 2015 Jan; 47(1):72-7. PubMed ID: 25143051
[TBL] [Abstract][Full Text] [Related]
33. A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma.
Kim MJ; Park SH; Lee JL; Lee SH; Lee SJ; Lim HY
BMC Urol; 2016 Aug; 16(1):46. PubMed ID: 27484998
[TBL] [Abstract][Full Text] [Related]
34. Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses.
Proskorovsky I; Benedict A; Negrier S; Bargo D; Sandin R; Ramaswamy K; Desai J; Cappelleri JC; Larkin J
BMC Cancer; 2018 Dec; 18(1):1271. PubMed ID: 30567533
[TBL] [Abstract][Full Text] [Related]
35. First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
Quhal F; Mori K; Bruchbacher A; Resch I; Mostafaei H; Pradere B; Schuettfort VM; Laukhtina E; Egawa S; Fajkovic H; Remzi M; Shariat SF; Schmidinger M
Eur Urol Oncol; 2021 Oct; 4(5):755-765. PubMed ID: 33757737
[TBL] [Abstract][Full Text] [Related]
36. Treatment and Outcome of Metastatic Renal Cell Carcinoma With Sarcomatoid Differentiation: A Single-Center, Real-World Analysis of Retrospective Data.
Janisch F; Kienapfel C; Fühner C; Klotzbücher T; Marks P; Hillemacher T; Meyer CP; Iwata T; Parizi MK; Sauter G; Fisch M; Shariat SF; Dahlem R; Rink M
Front Surg; 2021; 8():763271. PubMed ID: 34869564
[No Abstract] [Full Text] [Related]
37. Metformin Use and the Outcome of Metastatic Renal Cell Carcinoma Treated with Sunitinib or Pazopanib.
Fiala O; Ostašov P; Rozsypalová A; Hora M; Šorejs O; Šustr J; Bendová B; Trávníček I; Filipovský J; Fínek J; Büchler T
Cancer Manag Res; 2021; 13():4077-4086. PubMed ID: 34054309
[TBL] [Abstract][Full Text] [Related]
38. Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a single institution experience.
Matrana MR; Bathala T; Campbell MT; Duran C; Shetty A; Teegavarapu P; Kalra S; Xiao L; Atkinson B; Corn P; Jonasch E; Tannir NM
BJU Int; 2016 Aug; 118(2):264-71. PubMed ID: 26573089
[TBL] [Abstract][Full Text] [Related]
39. Stereotactic Radiotherapy for the Treatment of Patients With Oligo-progressive Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor: Data From the Real World.
Gebbia V; Girlando A; DI Grazia A; Fazio I; Borsellino N; Piazza D; Serretta V; Pergolizzi S; Pontoriero A; Firenze A; Valerio MR
Anticancer Res; 2020 Dec; 40(12):7037-7043. PubMed ID: 33288600
[TBL] [Abstract][Full Text] [Related]
40. A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03).
Procopio G; Claps M; Pircher C; Porcu L; Sepe P; Guadalupi V; De Giorgi U; Bimbatti D; Nolè F; Carrozza F; Buti S; Iacovelli R; Ciccarese C; Masini C; Baldessari C; Doni L; Cusmai A; Gernone A; Scagliarini S; Pignata S; de Braud F; Verzoni E
Tumori; 2023 Feb; 109(1):129-137. PubMed ID: 36447337
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
